ABBV ▲ +0.4% - AbbVie Inc. $ABBV - AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine AbbVie rose 0.4% following positive Phase 3 trial results for atogepant in menstrual migraine, a condition affecting a significant patient population with limited treatment options. The successful data expands the company's migraine portfolio and reinforces its competitive position in the preventive migraine market. 10-SEP-2026 08:56 AM ET